Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

August 12, 2022

Study Completion Date

September 11, 2022

Conditions
Anesthesia, Intravenous
Interventions
DRUG

remimazolam-based TIVA

In the remimazolam-based TIVA group, general anesthesia is induced and maintained with a continuous infusion of remimazolam using an infusion pump. In the remimazolam group, its antagonist, flumazenil, is administered at the end of surgery.

DRUG

propofol-based TIVA

In the propofol-based TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using an infusion pump (Orchestra®; Fresenius Vial, France).

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
collaborator

Hana Pharm Co., Ltd.

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT05047939 - Comparison of Recovery Profile After TIVA Between Remimazolam With Flumazenil and Propofol | Biotech Hunter | Biotech Hunter